Kornimate/medical-research-clean huggingface dataset:
high flow nasal cannula and exercise testing in chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: in this study the investigators will determine whether the use of high flow nasal cannula oxygen during test enhances exercise performance in copd patients on a treadmill.

design: interventional, crossover, randomized. the main goal of this study is to compare the maximum speed reached in an incremental load treadmill test (iltt) and max time tolerated in a constant treadmill load test (ctlt) while using high flow nasal cannula oxygen (hfnco). patients will be evaluated through two different kinds of tests: incremental load treadmill test (iltt) and constant treadmill load test (ctlt). each test will be conducted two times, once using high flow nasal cannula oxygen and the other breathing room air. in total, each patient will be evaluated four times on four different visits. the testing order will be randomized through stata. the following variables will be measured before, during and after each test: max speed reached in an incremental load test: km/h max time tolerate in a constant load test: in seconds oxygen saturation: % dyspnea: modified borg scale (0-10) cardiac rate: beats per minute respiratory rate: breaths per minute blood pressure: mmhg lower limbs fatigue: modified borg scale (0-10) global comfort according to the device used: visual analogue scale (vas) 0-10

Eligibility criteria:
inclusion criteria: * clinically stable defined as four weeks without exacerbation. * signed informed consent exclusion criteria: * long term oxygen therapy (ltot) or oxygen needs during exercise * any neuromuscular or cardiovascular condition that limits test performance * refusal to participate * contraindication for exercise

Keywords: pulmonary rehabilitation copd high flow nasal cannula hfnc aerobic capacity
pathological results of aggressive hepatocellular carcinomas treated using sirt

Conditions: Hepatocellular Carcinoma

Summary: the aim of our study is to analyze pathological analysis of surgically treated aggressive hepatocellular carcinomas after radio-embolization. the investigators aim to demonstrate that a higher dose results in better tumor response while respecting safety conditions, that is, no radiologically induced liver disease.


Eligibility criteria:
inclusion criteria: - aggressive hepatocellular carcinomas with vascular invasion, large tumors or multifocal distribution exclusion criteria: * other treatment after sirt (confounding effect) * contraindications for surgery
effect of an educational intervention about front of package labeling in children and caregivers.

Conditions: Overweight and Obesity; Malnutrition, Child

Summary: the goal of this clinical trial is to evaluate the effect of a digital educational intervention of front-of-package warning labeling on the selection and purchase of food in elementary school children and their caregivers. the main question it aims to answer is: * what is the effect of a digital educational intervention on front-of-package warning labeling on food selection in children from primary schools in mexico city, compared to a control group? participants will be randomized into two groups. * the control group, the dyads (caregiver-schoolchildren), will receive general nutritional education. * the intervention group, will also receive guidance on reading labels and raise awareness about the impact of consuming processed or ultra-processed foods on health. the intervention will be carried out through a web page with audiovisual material and all participants also will be asked to complete: * multiple-choice evaluation (5 questions) to ensure theoretical understanding of the topics * lunch register * 24-hour dietary recall * survey of food habits and consumption * validated food preference questionnaire * anthropometric measurements (weight, height, waist circumference, body mass index) * socioeconomic survey * participate in a simulated online selection and shopping of food and beverages. to see if the digital educational intervention in the front of package warning labeling in children and caregivers will improve the selection and purchase of foods.

third, fourth, and fifth-grade elementary school students and their caregivers from 4 primary schools, two public and two private, in mexico city, will participate. the schools will be chosen by simple random sampling. schools will be randomized into two groups: intervention and control. after approval from the directors of the primary schools, meetings will be held with parents to invite them to participate, they will be explained the objectives, activities, and duration of the intervention. they will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.

Eligibility criteria:
inclusion criteria: children: * third, 4th, and 5th grade students, both sexes, enrolled in the selected primary schools. * children with normal weight, overweight, and obesity. * children who sign the written informed consent. caregivers: * primary caregivers of any sex for children in 3rd, 4th, and 5th grade * caregivers with normal weight, overweight and obesity * parents who sign the written informed consent exclusion criteria: caregivers and children: * no internet access * no computer or mobile devices * who are participating in a weight reduction program, with or without pharmacological treatment

Keywords: front-of-package warning labeling food selection children caregivers nutritional education
avocado extract to improve glycemia in individuals with obesity (avail)

Conditions: Obesity

Summary: this two-arm, double blind, randomized clinical trial will compare the effect of an avocado extract, compared to placebo, on cardiometabolic outcomes in adults with obesity.

sixty eligible participants will be stratified by sex and randomly assigned to placebo or avocado extract supplementation group for 12 weeks. metabolic testing will be performed at baseline, and at the end of the intervention.

Eligibility criteria:
inclusion criteria: * men and women 25 - 65 years old * waist circumference (\>94cm in men and \>80cm in women) * bmi 30 - 40 kg/m2 * willingness to provide written informed consent and willingness to participate and comply with the study exclusion criteria: * women planning pregnancy during the course of the study or 3 months after completion of the study, or who are lactating * individuals diagnosed with type 1 or type 2 diabetes mellitus, liver or kidney diseases, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders (including inflammatory bowel disease and celiac), cardiovascular event in the previous 6 months, or any other condition deemed unstable * biochemical abnormalities or evidence at screening of disease including elevated liver enzymes alt and/or ast \>3 times normal range limit * not weight-stable (\< 5 % fluctuation in their body weight for past 6-months at study entry). * current or recent (within 12 months) treatment with medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, glucagon-like peptide-1 (glp-1) analogues \[i.e. exenatide\], thiazolidinediones or dpp-iv inhibitors \[i.e. 'gliptins'\]), medications affecting weight, appetite or gut motility (i.e. domperidone, cisapride, orlistat, phentermine, topiramate). participants who are taking stable doses (i.e. \> 12 months) of androgenic medications (i.e. testosterone), thyroxine, corticosteroids, anti-depressants (selective serotonin reuptake inhibitors), anti-hypertensives (ace-inhibitors, calcium channel blockers, beta-blockers, diuretics) and lipid lowering medications (statins, fibrates) will not be excluded. * participants who have had bariatric surgery * participants with conditions that may interfere with the ability to understand the requirements of the study.

Keywords: obesity avocado extract cardiometabolic health
multicentre prospective clinical database for the construction of predictive models on risk of intrauterine adhesion

Conditions: Database for Intrauterine Adhesion; Risk Factors for Intrauterine Adhesion; Risk Stratification and Prognostic Assessment; Intrauterine Adhesion

Summary: 1. to establish a follow-up database for uterine adhesions and a library of biological specimens for intrauterine adhesion. 2. using epidemiological surveys and biological analyses to screen risk factors for the development and prognosis of intrauterine adhesion. 3. predictive models based on clinical and biochemical indicators, specimen testing and hysteroscopic images are also combined with statistical analysis and machine learning algorithms to enable patients' risk stratification and prognostic assessment.


Eligibility criteria:
inclusion criteria: * previously diagnostic hysteroscopy confirmed adhesions combined with infertility or recurrent pregnancy loss (early pregnancy loss \>2) * desiring to conceive * ages between 20-45 years; * patients without gynecological endocrine disorders (e.g. pcos) and amh\>1ng/ml; * signing informed consent. exclusion criteria: * hysteroscopy contraindications; * hormone therapy contraindications; * pregnancy contraindications; * history of malignant pelvic tumor and radiotherapy; * severe hepatic or renal dysfunction; * complicated with hematological disorders (eg.platelet dysfunction, severe anemia, blood-borne infections); * male factor infertility(eg.seminal abnormalities).
a study of ly900014 and insulin degludec in participants with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: in this study, participants with type 1 diabetes (t1d) will take the study drug ly900014 and insulin degludec. the reason for this study is to evaluate the amount of time with glucose values within target range.


Eligibility criteria:
inclusion criteria: * participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year * participants must be using continuous glucose monitoring (cgm) with total cgm use ≥ 2 months in the prior 6 months * participants must have been on the same type of short acting insulin (humalog u-100, novolog, admelog, or apidra) for at least 30 days prior to screening * participants must have been treated with long-acting insulin degludec u-100 for at least 30 days prior to screening exclusion criteria: * participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening * participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening * participants must not be taking certain diabetes medications that are not allowed for study participation
immunogenicity, safety and 1 year persistence of antibodies after either one or two doses of meningococcal acwy conjugate vaccine in healthy children 2 through 10 years of age.

Conditions: Meningococcal Disease; Infections, Meningococcal

Summary: this study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of novartis menacwy conjugate vaccine, given 2 months apart, versus one dose of novartis menacwy conjugate vaccine in children 2 through 10 years of age.


Eligibility criteria:
inclusion criteria: * healthy children, 2 to 10 years of age who have up to date routine childhood vaccination, according to u.s. acip recommendations exclusion criteria: 1. unwilling or unable to give written informed assent or consent to participate in the study. 2. perceived to be unreliable or unavailable for the duration of the study period. 3. previous confirmed or suspected disease caused by n. meningitidis. 4. previously immunized with a meningococcal vaccine (licensed or investigational). 5. receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study. 6. receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine. (certain exceptions influenza vaccines apply) 7. significant acute infection within the 7 days prior to enrolment or body temperature of 38°c or greater within 3 days prior to enrolment. 8. previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of guillain-barre syndrome. 9. history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components 10. impairment/alteration of immune function, either congenital or acquired or resulting from (for example): * receipt of immunosuppressive therapy, * receipt of immunostimulants, * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives. 11. known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.

Keywords: prevention of meningococcal disease, children, vaccine
education-based physical therapy approach for adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: this study aims, by means of a randomized control trial, to investigate which treatment method (corticoid injection + physiotherapy with a focus on manual therapy and home-exercises versus corticosteroid injection + physiotherapy with focus on education and supported home exercises) gives better results on clinically relevant outcomes (range of glenohumeral motion, psychological factors, pain, shoulder function, quality of life) and on parameters derived from arthroscopic glenohumeral investigation by means of mri. furthermore, associations between (1) the results on the mri investigation, (2) the range of glenohumeral motion, (3) shoulder function and pain, and (4) psychological factors will be assessed at different time-points (before and at 6-12-18 and 52 weeks after the first injection).


Eligibility criteria:
inclusion criteria: * 50 % loss of passive gh external rotation motion, together with motion losses greater than 25% in at least two other gh movements, as compared to the unaffected side * the pain accompanying the motion losses has to be present for at least one month. during that month, the pain and mobility deficits have to be stable or get worse exclusion criteria: * bilateral frozen shoulder * systemic and/or neurologic disease or a self-reported pathologic condition of the cervical/thoracic region, elbow or wrist/hand
start the conversation: evaluating implementation of a multi-level prep initiative for black cisgender women in nola

Conditions: Preexposure Prophylaxis; HIV Infections

Summary: the study objectives are to: * evaluate implementation outcomes from piloting the start the conversation initiative * assess initial indicators of clinical effectiveness among patients engaged in the start the conversation initiative these outcomes will be assessed qualitatively through in-depth interviews (idis), debriefing sessions with gyn residents and leadership, medical chart reviews and/or de-identified epic queries, training records, discussions with the black women and prep (bwap) task force, and social media metrics.


Eligibility criteria:
inclusion criteria: * lsu gyn residents * black cisgender women eligible for prep per cdc guidelines
evaluation of 3 intraocular lenses following lens extraction

Conditions: Cataract

Summary: the objective of this study is to evaluate the efficacy and subject satisfaction with three different fda approved lenses for adults over 40 years of age who desire a reduction in spectacle dependence.


Eligibility criteria:
inclusion criteria: * subjects must have a clinically documented diagnosis of age-related bilateral cataracts that are considered amenable to treatment with standard phacoemulsification cataract extraction. * subjects must require a spherical lens power from 10.00 d to 33.00 d * subjects must have the potential for corrected distance visual acuity (cdva) of 20/32 or better in both eyes, as documented by a potential acuity meter exclusion criteria: * subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome. zonular rupture during cataract surgery may affect postoperative centration, tilt, and stability of the lens. * subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis. * subjects with visually significant diabetic retinopathy (proliferative or non-proliferative) which reduces potential acuity to 20/32 or worse.

Keywords: intra ocular lens ocular surgery phacoemulsification
host response to infection and treatment in lymphatic filarial disease in india

Conditions: Lymphatic Filarial Disease

Summary: patients admitted on this protocol will have, or be suspected of having, one of the lymphatic filarial infections affecting humans. after routine clinical evaluation they will be studied in depth immunologically, and their blood cells and/or serum will be collected to provide reagents (eg., specific antibodies, t cell clones, etc.) that will be used in the laboratory to address the broader questions of immunodiagnosis, immunoregulation, immunopathology and immunoprophylaxis. careful observations of the patients' clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. it is anticipated both that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the immunologic responses unique to filarial or other helminthic infections.

this study is designed to determine the presence of and the immune response to filarial and stronglyloides infections in an area endemic for both infections in south india. this study will aim to examine the presence of filarial and strongyloides stercoralis infection at a community level as well as in hospital settings. after routine clinical evaluation and screening, individuals enrolled in this protocol will be studied in depth immunologically, and their blood cells and/or serum will be collected to address the broader questions of immunodiagnosis, immunoregulation and immunopathology. careful observations of the individual s clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. in addition to infected individuals, this protocol will also be used to study individuals with filarial pathology and endemic normal individuals. this will enable us to characterize the immunological profiles of infected, uninfected and diseased individuals in an endemic area and provide greater insight into the pathogenesis of lymphatic filarial disease as well as the immunology of strongyloides infection.

Eligibility criteria:
* inclusion criteria: age 18-75 years. ability to give informed consent. exclusion criteria: pregnant or nursing women will be excluded from the treatment arm of the study. less than 18 years of age; greater than 75 years of age.

Keywords: filarial parasites wuchereria bancrofti brugia malayi diethylcarbamazine (dec) ivermectin
a phase ib study of panobinostat (lbh589) in combination with 5-azacitidine for myelodysplastic syndromes (mds), chronic myelomonocytic leukemia (cmml) or acute myeloid leukemia (aml) patients

Conditions: Myelodysplastic Syndromes (MDS); Chronic Myelomonocytic Leukemia (CMML); Acute Myeloid Leukemia (AML)

Summary: the purpose of this study is to confirm the safety and tolerability of oral panobinostat (pan) in combination with a fixed dose of 5-azacitidine (5-aza) in adult japanese patients with myelodysplastic syndromes (mds), chronic myelomonocytic leukemia (cmml) or acute myeloid leukemia (aml).


Eligibility criteria:
inclusion criteria: 1. japanese patients who are candidates for treatment with 5-aza and present with one of the following: * intermediate-2 or high-risk mds according to the international prognostic scoring system (ipss). or * aml with multilineage dysplasia and maximum of 30% blasts (former raeb-t according to fab) or cmml 2. patient has an ecog performance status of ≤ 2 3. patients must have the following laboratory values unless elevations are considered due to mds or leukemia: ast/sgot and/or alt/sgpt ≤ 2.5 x uln; serum creatinine ≤ 1.5 x uln; serum bilirubin (total and direct) ≤ 2 x uln; electrolyte panel without clinically relevant abnormalities exclusion criteria: 1. patient who is planned for or has history of hematopoietic stem-cell transplantation (hsct) 2. patients with relapsed/refractory aml 3. patient is receiving concurrent anti-cancer therapy 4. patient has received prior treatment with deacetylase inhibitors (daci) 5. patient has received prior treatment with 5-aza or 6-aza-2'-deoxycytidine (decitabine) 7. patient has shown suspected hypersensitivity to 5-aza or mannitol 8. patients with impaired cardiac function 9. patient taking medications with relative risk of prolonging the qt interval or inducing torsade de pontes if such treatment cannot be discontinued or switched to a different medication prior to starting study treatment 10. patients with clinical evidence of relevant mucosal or internal bleeding 11. patient has any other concurrent severe and/or uncontrolled medical conditions other protocol-defined inclusion/exclusion criteria may apply

Keywords: myelodysplastic syndromes mds chronic myelomonocytic leukemia cmml acute myeloid leukemia aml panobinostat lbh589 5-aza azacitidine